Approximately 10% to 15% of HR-positive, HER2-negative breast cancer patients experience visceral crises,[11] which may present with diffuse liver metastases, meningeal involvement, bone marrow infiltration, or pulmonary lymphangitic carcinomatosis (PLC). Here, ERBB2 is linked to breast carcinoma.